# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 (317) 521 - 3723

Contact Person: Theresa A. Bush

Date PreparedJune 6, 2008

# Device Name

Proprietary name: (1) Elecsys Toxo IgG Immunoassay (2) Elecsys PreciControl Toxo IgG

Common name: (1) Toxoplasma IgG assay () PreciControl Toxo IgG

Classification name: (1) Toxoplasma gondi serological reagents (2) Single (specified) analyte controls (assaycd and unassayed)

# Elecsys Toxo IgG Test System

# Device Description

(1) The Elecsys Toxo IgG Immunoassay is a two-step sandwich immunoassay with streptavidin microparticles and electrochemiluminescence detection. In the first incubation, $1 0 \mu \mathrm { L }$ of sample, a biotinylated recombinant T. gondiispecific antigen, and a T. gondi-specific recombinant antigen labeled with a ruthenium complex a form a sandwich complex. Then, after addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin. The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier. Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode. A human serum-based calibrator is provided with the test kit, and the recommended control material is PreciControl Toxo IgG.

(2) The Elecsys Precicontrol Toxo IgG contains two levels of human serum with Toxo IgG antibodies.

# Intended use

(1) The Elecsys Toxo IgG immunoassay is for the in vitro quantitative determination of IgG antibodies to Toxoplasma gondi in human serum and Li-heparin, K3-EDTA, and sodium citrate plasma. This assay may be used as an aid in the assessment of immune status and as an aid in the diagnosis of primary infection.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the Elecsys and cobas e immunoassay analyzers.

(2) Elecsys PreciControl Toxo IgG is used for quality control of the Elecsys Toxo IgG immunoassay on the Elecsys and cobas e immunoassay analyzers.

# Indications for Use

(1) The Elecsys Toxo IgG assay may be used as an aid in the assessment of immune status and as an aid in the diagnosis of primary infection.

# Substantial equivalence

The Elecsys Toxo IgG Test System is substantially equivalent to the VIDAS TOXO IgG II Test System cleared in K993319

# 510(k) Summary, Continued

Substantial equivalence - similarities

<table><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Elecsys Toxo IgG immunoassay is forthe in vitro quantitative determination ofIgG antibodies to Toxoplasma gondi inhuman serum and Li-heparin, K3-EDTA,and sodium citrate plasma. This assay isintended for use as an aid in the assessmentof immune status and as an aid in thediagnosis of primary infection.The electrochemiluminescenceimmunoassay &quot;ECLIA&quot; is intended for useon the Elecsys and cobas e immunoassayanalyzers.NOTE: This assay has not been cleared bythe FDA for blood/plasma donor screening.</td><td rowspan=1 colspan=1>The VIDAS Toxo IgG II (TXG) assayis an automated quantitative test for useon the VIDAS analyzer for themeasurement of anti-toxoplasma IgGin human serum using the ELFAtechnique (Enzyme LinkedFluorescence Assay). It is intended foruse as an aid in determination ofimmune status. This test is not intendedfor use in screening blood donors.</td></tr><tr><td rowspan=1 colspan=1>Indication forUse</td><td rowspan=1 colspan=1>aid in the assessment of immune status andas an aid in the diagnosis of primaryinfection.</td><td rowspan=1 colspan=1>an aid in determination of immunestatus</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Electrochemiluminescent Immunoassay</td><td rowspan=1 colspan=1>enzyme-linked fluorescentimmunoassay (ELFA)</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human serum, lithium heparin plasma,potassium EDTA plasma and sodium citrateplasma.When citrated plasma is used, the values foundare approximately 15% lower</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatform</td><td rowspan=1 colspan=1>Roche Elecsys 2010/ cobas e 411 andMODULAR ANALYTICS E170 (Elecsysmodule)/ cobas e 601 analyzers.</td><td rowspan=1 colspan=1>VIDAS ® Instrument</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Included in kit</td><td rowspan=1 colspan=1>Included in kit</td></tr><tr><td rowspan=1 colspan=1>Calibrator levels</td><td rowspan=1 colspan=1>Two</td><td rowspan=1 colspan=1>One</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>Human serum</td></tr><tr><td rowspan=1 colspan=1>CalibratorStability</td><td rowspan=1 colspan=1>After opening at 2-8C: 8 weeksOn Elecsys 2010/ cobas e 411: up to 5hoursOn E170/ cobas e 601: use only once</td><td rowspan=1 colspan=1>Store between 2-8 °C.</td></tr><tr><td rowspan=1 colspan=1>Calibrationfrequency</td><td rowspan=1 colspan=1>Once per reagent lot andAfter 1 month when using samereagent lotAfter 7 days when using samereagent kitAs required per QC findings orpertinent regulations</td><td rowspan=1 colspan=1>Every new reagent lotEvery 14 days</td></tr></table>

# Elecsys Toxo IgG Test System

<table><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>PreciControl Toxo IgG (sold separately)</td><td rowspan=1 colspan=1>Positive and negative control includedin kit.</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>3rd International Standard for Anti-Toxoplasma serum (TOXM) from NIBSC,UK</td><td rowspan=1 colspan=1>WHO standard</td></tr><tr><td rowspan=1 colspan=1>Reagent Stability</td><td rowspan=1 colspan=1>Unopened 2-8°C - up to expirationOpened 2-8°C  12 weeksOnboard- 2 weeks or 12 weeks (if storedalternately in refrigerator and on theanalyzer- ambient temperature 20-25°C; upto 84 hours opened in total.)</td><td rowspan=1 colspan=1>Unopened kit: Store at 2-8°C. Do notfreezeAfter opening: Store at 2-8°C . Pouchshould be immediately resealed withdessicant ; stable until expiration date</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>0.125-650 IU/mL</td><td rowspan=1 colspan=1>Linear up to 250 or 300 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>Intrassay: (range of values)Low Control: SD = 0.02-0.05 IU/mLHigh Control: 2.02-4.78 CV %Plasma Samples &lt; 1 IU/mL:0.014-0.079 SD IU/mLPlasma Samples &gt; 1 IU/mL:CV 1.76-3.09%Inter-assay:Low Control: SD 0.047 -0.077 IU/mLHigh Control: CV 2.9-5.1 %Plasma Samples &lt; 5 IU/mL:SD 0.039-0.089 IU/mLPlasma Samples &gt; 5 IU/mL:CV 2.7 - 5.3%</td><td rowspan=1 colspan=1>Within-run:Negative: SD = 0.25 IU/mLLow positive: 5.13% CVHigh positive: 7.21 % CVTotal:Negative: SD = 0.43 IU/mLLow positive: 6.70% CVHigh positive: 10.88 % CV</td></tr><tr><td rowspan=1 colspan=1>Limit of Blank</td><td rowspan=1 colspan=1>0.130 IU/mL</td><td rowspan=1 colspan=1>Not stated.</td></tr><tr><td rowspan=1 colspan=1>Limit ofDetection</td><td rowspan=1 colspan=1>0.175 IU/mL</td><td rowspan=1 colspan=1>Not stated.</td></tr></table>

<table><tr><td rowspan=22 colspan=1>AnalyticalSpecificity</td><td rowspan=22 colspan=6>193 specimens were tested representing a    No crossreactivity or interference duevariety of disease. Results shown in table:    to RF, ANA and EBV.Elecesys   Elecsys   Blecsys   ElecsysCross-     No.  Toxo IgG  Toxo IgG/ Toxo IgG/  ToRo lgG/reactant     tosted Refrtnce  Referance  Reference  ReferenceNoy/Neg  N   Neg/Pos   Pom/PosAMA      1.5     3       0       0       11ANA      26     8                 0       15Chlamydia    4                        0       2CMV       B     0       0       0        8EBV       9     4                           4Go orbea    5     2                 0        3HAV       10HBV       23     14HCV       1     5HIV        13     10HSVT       8               0Infuenza     16     12Malaria      10     4Parvo B19    10     9Rubella      10     4Syphilis      5                        0TPAH      3                        0VZV        7Sub total     186    93                          89Total       1993                  186O  E oT at  t  n ap  rat al te El Tssn e  tn  </td></tr><tr><td rowspan=1 colspan=1>Cross-reactant</td><td rowspan=1 colspan=1>No.tosted</td><td rowspan=1 colspan=1>ElecesysToxo IgGRefrtnceNoy/Neg</td><td rowspan=1 colspan=1>ElecsysToxo IgG/ReferanceN</td><td rowspan=1 colspan=1>BlecsysToxo IgG/ReferenceNeg/Pos</td><td rowspan=1 colspan=1>ElecsysToRo lgG/ReferencePom/Pos</td></tr><tr><td rowspan=1 colspan=1>AMA</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>ANA</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Chlamydia</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>EBV</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Go orbea</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>HAV</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HBV</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HCV</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HIV</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HSVT</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Infuenza</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Malaria</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Parvo B19</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Rubella</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>TPAH</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>VZV</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sub total</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>89</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1993</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Interferences</td><td rowspan=1 colspan=5>The assay is unaffected by icterus (bilirubin&lt; 684 μmol/L or &lt; 40 mg/dL), hemolysis(Hb &lt; 1.24 mmol/L or &lt; 2 g/dL), lipemia(Intralipid &lt; 2000 mg/dL), and biotin &lt; 246nmol/L or &lt; 60 ng/mL.Criterion: Recovery of positive sampleswithin ± 20% of initial value.Rheumatoid factor was not observed tocause any consistent bias. However,elevated levels of RF may lead to erroneousresults in some instances No interferencedue to 18 commonly used pharmaceuticalsor to spiramycine, sulfadiazine, folic acid,and pyrimethamine.</td><td rowspan=1 colspan=1>Avoid using obviously hemolyzed,lipemic, or icteric samples.</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=5>In a prospective study of 515 subjects froma United States reference laboratory, theprevalence of IgG antibodies to T. gondiiwas shown to be 37.1%. The prevalencewas 42.7% in pregnant women, 43.6% inmales, 36.6% in females.The prevalence from a European study of470 prospectively collected samples was37.4%. The prevalence was 9.6% inpregnant women, 41.2% in males and11.2% in females. Prevalence in the groupof unknown gender was 65.1%.</td><td rowspan=1 colspan=1>The prevalence of toxoplasmosis variesdepending upon geographical location,age and gender of the populationstudied, specimen collection andhandling, and other factors. In Europe,the prevalence rate ranges from 20% to85%. In the United States, theprevalence is lower: 12% to 41%.Prevalence in other countries can varyfrom 18% to 65%</td></tr></table>

# Elecsys Toxo IgG Test System

<table><tr><td>Method Comparison</td><td>US Routine Clinical Specimens</td></tr><tr><td></td><td>Negative Agreement: 93.4 % (310/332) 90.1%-95.8% Positive Agreement 100 % (183/183) 98.0% - 100.0%</td></tr><tr><td></td><td></td></tr><tr><td></td><td>European Site Prospective study results:</td></tr><tr><td></td><td>Negative Agreement: 91.1% (288/316) 87.5  94.0 %</td></tr><tr><td></td><td>Positive Agreement: 99.3% (151/152) 96.4-100.0%</td></tr><tr><td></td><td>European Site Frozen sample results:</td></tr><tr><td></td><td>Negative Agreement: 68.1 (32/47) 52.9 -80.9% Positive Agreement: 9999.7% (378/379) 98.5-100.0</td></tr><tr><td></td><td></td></tr></table>

Ms. Theresa Bush Regulatory Affairs Principal Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250

# JUN -9 2008

Re: K073501 Trade/Device Name: Elecsys® Toxo IgG Immunoassay and Elecsys ® PreciControl Toxo IgG Regulation Number: 21 CFR 866.3780 21 CFR 862.1660 Regulation Name: Toxoplasma gondii Serological Reagents Quality Control Material (assayed and unassayed) Regulatory Class: Class II Product Code: LGD, JJX Dated: April 30, 2008 Received: May 1, 2008

Dear Ms. Bush:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class Ⅱ (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification.The FDA finding of substantial equivalence of your device to a legally marke preicate devi results n clasifiatin or yourdeviceand thus permits yourdevi to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain othcr general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

Sall atty

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

Enclosure

# Elecsys Toxo IgG Test System

# Indications for Use

510(k) Number (if known): k 0 7350 1

Device Name: Elecsys $\textsuperscript { \textregistered }$ Toxo IgG Immunoassay

Indications For Use:

The Elecsys Toxo IgG immunoassay is for the in vitro quantitative determination of IgG antibodies to Toxoplasma gondi in human serum and Li-heparin, K3-EDTA, and sodium citrate plasma. This assay is intended for use as an aid in the assessment of immune status and as an aid in the diagnosis of primary infection.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the Elecsys and cobas e immunoassay analyzers.

NOTE:This ssy s ot bee cear y the FDA o/pla ooee

Prescription Use _XXX And/Or Over the Counter Use (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/02dc53baa2dd09010f71bed873a483af532d2a3991bf3a8777264bbbdd5928d2.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

Elecsys Toxo IgG Test System

# Indications for Use

510(k) Number (if known): k0 7 350 1

Device Name: Elecsys PreciControl Toxo IgG

Indications For Use:

Elecsys PreciControl Toxo IgG is used for quality control of the Elecsys Toxo IgG immunoassay on the Elecsys and cobas e immunoassay analyzers.

And/Or

Prescription Use XXX (21 CFR Part 801 Subpart D)

Over the Counter Use (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/4d370c5ea7e7f3208f14215231680732d457bb9037fea323d3b7a9d901739dbe.jpg)

DIvision Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety